Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CTI investigated by SEC

This article was originally published in The Gray Sheet

Executive Summary

The Securities & Exchange Commission and U.S. Attorney request documents from Computerized Thermal Imaging's management related to possible insider trading malfeasance, company states in recent 10-K filing. While CTI maintains the allegations are without merit, it believes the charges will greatly impair its ability to raise funds. FDA's Radiological Devices Advisory panel voted against approval of the company's BCS 2100 breast imaging system; CTI continues to work with the agency to remedy deficiencies in its application (1"The Gray Sheet" May 25, 2003, In Brief)...

You may also be interested in...

CTI working to overturn FDA decision

Computerized Thermal Imaging reports May 22 it has "provided additional analysis and...had productive discussions with the FDA staff" on the agency's "non-approvable" letter for BCS 2100 thermal breast imaging system. Rejection of the PMA followed a December panel meeting in which members faulted the Portland, Ore. firm's 173-patient "post-hoc" retrospective study as inadequately powered (1"The Gray Sheet" Dec. 16, 2002, p. 11)...

EWG Study Suggests More Than One In 10 Talc-Based Cosmetics Contain Asbestos

The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.

Atlas Biomed Unlocking Japan’s OTC Market With Direct-To-Consumer DNA And Microbiome Tests

Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus. 




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts